Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
93.98
(
-1.09%
)
Bitcoin
76,375.39
(
0.06%
)
News Focus
News Focus
Post# of 80490
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 85
Posts 12832
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: jq1234 post# 74202

Sunday, 06/26/2016 1:02:05 PM

Sunday, June 26, 2016 1:02:05 PM

Post# of 80490
"INCY was more interested in EU operation rather than ponatinib, otherwise they would have agreed to pay much higher portion of OPTIC-2L trial expense because it is a completely outside of US trial."

Bingo! The $15 million toward the trial from INCY was nothing but a token. Actually, it would have come across as a better for Ariad if they didn't contribute anything. $15 million is so nothing..
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today